References
- Perez‐Verdia A., Angulo F., Hardwicke F. L., Nugent K. M. Acute cardiac toxicity associated with high‐dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005; 25: 1271–6
- Gasser A. B., Tieche M., Brunner K. W. Neurologic and cardiac toxicity following iv application of methotrexate. Cancer Treat Rep 1982; 66: 1561–2
- Kettunen R., Huikuri H. V., Oikarinen A., Takkunen J. T. Methotrexate‐linked ventricular arrhythmias. Acta Derm Venereol 1995; 75: 391–2
- Borek G., Jenzer H. R., Frey L. D., Locher J. T. Repetitive exercise induced ventricular tachycardia in a patient with rheumatoid arthritis taking low dose methotrexate. J Rheumatol 1992; 19: 1004–5
- Fuskevag O. M., Kristiansen C., Lindal S., Aarbakke J. Maximum tolerated doses of methotrexate and 7‐hydroxy‐methotrexate in a model of acute toxicity in rats. Cancer Chemother Pharmacol 2000; 46: 69–73
- Fichtlscherer S., Rossig L., Breuer S., Vasa M., Dimmeler S., Zeiher A. M. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001; 104: 3023–5
- Vezmar S., Becker A., Bode U., Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92–104
- van Ede A. E., Laan R. F., Blom H. J., De Abreu R. A., van de Putte L. B. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277–92
- Mallet M. L. Proarrhythmic effects of adenosine: a review of the literature. Emerg Med J 2004; 21: 408–10